Verzenio
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Verzenio in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Verzenio.
40
Global Revenue Ranking
17
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Verzenio
This year marks the congress’s 50th anniversary, with the theme: Many journeys. One global community
The findings are based on Lilly’s phase 3 monarchE trial
The decision removes the previous 20% Ki-67 score requirement for patient selection
Results were shared in The Lancet Oncology and at the San Antonio Breast Cancer Symposium
The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy
Revenues in the third quarter of 2021 were driven by volume growth in new medicines, but earnings per share were a fraction below analysts’ predictions
Verzenio is the first addition to adjuvant endocrine therapy approved by the FDA in nearly two decades for the treatment of HR+ HER2- early breast cancer
Lilly will use Lycia Therapeutics’ novel technology to inhibit “intractable” targets in its therapeutic areas of focus, including immunology and pain
NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS
Verzenio plus endocrine therapy reduced the risk of patients developing metastatic disease by 39%
Data shows the ‘longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients’
FDA recently removed emergency authorisation for bamlanivimab monotherapy
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology